Fintel reports that on September 14, 2023, HC Wainwright & Co. reiterated coverage of Atyr Pharma (NASDAQ:LIFE) with a Buy recommendation.
Analyst Price Forecast Suggests 1,342.93% Upside
As of August 31, 2023, the average one-year price target for Atyr Pharma is 23.66. The forecasts range from a low of 12.12 to a high of $36.75. The average price target represents an increase of 1,342.93% from its latest reported closing price of 1.64.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Atyr Pharma is 7MM, a decrease of 32.07%. The projected annual non-GAAP EPS is -1.83.
What is the Fund Sentiment?
There are 77 funds or institutions reporting positions in Atyr Pharma. This is an increase of 2 owner(s) or 2.67% in the last quarter. Average portfolio weight of all funds dedicated to LIFE is 0.08%, a decrease of 36.09%. Total shares owned by institutions increased in the last three months by 1.13% to 35,724K shares. 
The put/call ratio of LIFE is 0.04, indicating a bullish outlook.
What are Other Shareholders Doing?
Federated Hermes holds 10,190K shares representing 17.86% ownership of the company. No change in the last quarter.
FKASX - Federated Kaufmann Small Cap Fund Shares holds 5,264K shares representing 9.23% ownership of the company. In it's prior filing, the firm reported owning 2,900K shares, representing an increase of 44.91%. The firm increased its portfolio allocation in LIFE by 69.25% over the last quarter.
KAUAX - Federated Kaufmann Fund Shares holds 4,785K shares representing 8.39% ownership of the company. In it's prior filing, the firm reported owning 2,265K shares, representing an increase of 52.66%. The firm increased its portfolio allocation in LIFE by 86.85% over the last quarter.
Stonepine Capital Management holds 4,627K shares representing 8.11% ownership of the company. In it's prior filing, the firm reported owning 4,826K shares, representing a decrease of 4.29%. The firm increased its portfolio allocation in LIFE by 10.47% over the last quarter.
Tikvah Management holds 2,461K shares representing 4.31% ownership of the company. No change in the last quarter.
Atyr Pharma Background Information
(This description is provided by the company.)
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
